Application value of gadobutrol in contrast-enhanced magnetic resonance angiography in abdominal artery angiography: a prospective multicenter study_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

LIU Xijiao ¹ , LI Zhengyan ¹ , ZHANG Weiwei ¹ , DIAO Yike ¹ , FU Yu ² , XU Yikai ³ , WANG Jing ⁴ , REN Jing ⁵ , SHEN Wen ⁶ ,  SONG Bin ¹

1. Department of Radiology, West China hospital, Sichuan University, Chengdu 610041, P. R. China;
2. Department of Radiology, The First Hospital, Jilin University, Changchun 130021, P. R. China;
3. Department of Radiology, Nanfang Hospital, Southern Medical University, Guangzhou, 510530, P. R. China;
4. Department of Radiology, The Third Affiliated Hospital of Zhongshan University, Guangzhou 510630, P. R. China;
5. Department of Radiology, Sichuan Cancer Hospital, Chengdu 610041, P. R. China;
6. Department of Radiology, Tianjin First Central hospital, Tianjin 300192, P. R. China;

Corresponding author：

SONG Bin, Email: cjr.songbin@vip.163.com

Keywords：

gadobutrol; magnetic resonance angiography; artery; abdomen

DOI：

10.7507/1007-9424.202003114

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To explore the value of gadobutrol enhanced magnetic resonance angiography (MRA) in abdominal artery angiography.Methods The patients were prospectively included for gadobutrol enhanced MRA examination from December 2014 to December 2015. The image quality was assessed by two radiologists. The subjective score and signal intensity were measured for the large and medium arteries, and the subjective score for the small artery was recorded. The Kappa consistency analysis was used to assess the two radiologists’ subjective score.Results All 112 patients were enrolled in this study, 96 of whom were included for the physical examination, 16 of whom were included for the liver tumors. No adverse reactions were found in these patients. The MRA images of 2 patients were affected by the severe respiratory artifact. The MRA images of the other 110 cases were clear and could well show the origins, shapes of large and medium arteries and small arteries. The subjective scores were 21.22±1.93 and 6.24±1.33 of the large and medium arteries and small arteries, respectively. The values of signal noise ratio and contrast signal noise ratio of the large and medium arteries were 1 093.27±331.71 and 897.27±333.29, respectively. The Kappa values of the two radiologists’ subjective score were 0.782 and 0.772 for the large and medium arteries and small arteries, respectively.Conclusions Gadobutrol enhanced MRA can clearly display large and medium arteries, and can also display some small arteries. It has a good application value in abdominal artery angiography.

Citation： LIU Xijiao, LI Zhengyan, ZHANG Weiwei, DIAO Yike, FU Yu, XU Yikai, WANG Jing, REN Jing, SHEN Wen, SONG Bin. Application value of gadobutrol in contrast-enhanced magnetic resonance angiography in abdominal artery angiography: a prospective multicenter study. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2020, 27(5): 615-618. doi: 10.7507/1007-9424.202003114 Copy

1.	Hahn G, Sorge I, Gruhn B, et al. Pharmacokinetics and safety of gadobutrol-enhanced magnetic resonance imaging in pediatric patients. Invest Radiol, 2009, 44(12): 776-783.
2.	Bhargava R, Noga M. Safety and efficacy of gadobutrol-enhanced MRI in patients aged under 2 years—a single-center, observational study. Magn Reson Insights, 2013, 6: 1-12.
3.	Arnoldussen CWKP, Lam Y, Ito N, et al. Gadobutrol versus gadofosveset-trisodium in MR venography of the lower extremities. Eur Radiol, 2017, 27(12): 4986-4994.
4.	Haneder S, Attenberger UI, Schoenberg SO, et al. Comparison of 0.5 M gadoterate and 1.0 M gadobutrol in peripheral MRA: a prospective, single-center, randomized, crossover, double-blind study. J Magn Reson Imaging, 2012, 36(5): 1213-1221.
5.	Hoelter P, Lang S, Weibart M, et al. Prospective intraindividual comparison of gadoterate and gadobutrol for cervical and intracranial contrast-enhanced magnetic resonance angiography. Neuroradiology, 2017, 59(12): 1233-1239.
6.	Tombach B, Heindel W. Value of 1.0-M gadolinium chelates: review of preclinical and clinical data on gadobutrol. Eur Radiol, 2002, 12(6): 1550-1556.
7.	Staks T, Schuhmann-Giampieri G, Frenzel T, et al. Pharmacokinetics, dose proportionality, and tolerability of gadobutrol after single intravenous injection in healthy volunteers. Invest Radiol, 1994, 29(7): 709-715.
8.	Forsting M, Palkowitsch P. Prevalence of acute adverse reactions to gadobutrol—a highly concentrated macrocyclic gadolinium chelate: review of 14 299 patients from observational trials. Eur J Radiol, 2010, 74(3): e186-e192.
9.	Prince MR, Lee HG, Lee CH, et al. Safety of gadobutrol in over 23 000 patients: the GARDIAN study, a global multicentre, prospective, non-interventional study. Eur Radiol, 2017, 27(1): 286-295.
10.	马春忠, 高继斌. 含钆 MR 对比剂与肾源性系统性纤维化的关系. 中国临床医学影像杂志, 2009, 20(1): 53-54.
11.	许俊. 高浓度磁共振对比剂钆布醇的理化性质及临床应用. 放射学实践, 2016, 31(7): 666-669.
12.	Hadizadeh DR, Jost G, Pietsch H, et al. Intraindividual quantitative and qualitative comparison of gadopentetate dimeglumine and gadobutrol in time-resolved contrast-enhanced 4-dimensional magnetic resonance angiography in minipigs. Invest Radiol, 2014, 49(7): 457-464.
13.	Tombach B, Benner T, Reimer P, et al. Do highly concentrated gadolinium chelates improve MR brain perfusion imaging? Intraindividually controlled randomized crossover concentration comparison study of 0.5 versus 1.0 mol/L gadobutrol. Radiology, 2003, 226(3): 880-888.
14.	Fabrega-Foster KE, Agarwal S, Rastegar N, et al. Efficacy and safety of gadobutrol-enhanced MRA of the renal arteries: Results from GRAMS (Gadobutrol-enhanced renal artery MRA study), a prospective, intraindividual multicenter phase 3 blinded study. J Magn Reson Imaging, 2018, 47(2): 572-581.
15.	Luetkens JA, Kupczyk PA, Doerner J, et al. Respiratory motion artefacts in dynamic liver MRI: a comparison using gadoxetate disodium and gadobutrol. Eur Radiol, 2015, 25(11): 3207-3213.

1. Hahn G, Sorge I, Gruhn B, et al. Pharmacokinetics and safety of gadobutrol-enhanced magnetic resonance imaging in pediatric patients. Invest Radiol, 2009, 44(12): 776-783.
2. Bhargava R, Noga M. Safety and efficacy of gadobutrol-enhanced MRI in patients aged under 2 years—a single-center, observational study. Magn Reson Insights, 2013, 6: 1-12.
3. Arnoldussen CWKP, Lam Y, Ito N, et al. Gadobutrol versus gadofosveset-trisodium in MR venography of the lower extremities. Eur Radiol, 2017, 27(12): 4986-4994.
4. Haneder S, Attenberger UI, Schoenberg SO, et al. Comparison of 0.5 M gadoterate and 1.0 M gadobutrol in peripheral MRA: a prospective, single-center, randomized, crossover, double-blind study. J Magn Reson Imaging, 2012, 36(5): 1213-1221.
5. Hoelter P, Lang S, Weibart M, et al. Prospective intraindividual comparison of gadoterate and gadobutrol for cervical and intracranial contrast-enhanced magnetic resonance angiography. Neuroradiology, 2017, 59(12): 1233-1239.
6. Tombach B, Heindel W. Value of 1.0-M gadolinium chelates: review of preclinical and clinical data on gadobutrol. Eur Radiol, 2002, 12(6): 1550-1556.
7. Staks T, Schuhmann-Giampieri G, Frenzel T, et al. Pharmacokinetics, dose proportionality, and tolerability of gadobutrol after single intravenous injection in healthy volunteers. Invest Radiol, 1994, 29(7): 709-715.
8. Forsting M, Palkowitsch P. Prevalence of acute adverse reactions to gadobutrol—a highly concentrated macrocyclic gadolinium chelate: review of 14 299 patients from observational trials. Eur J Radiol, 2010, 74(3): e186-e192.
9. Prince MR, Lee HG, Lee CH, et al. Safety of gadobutrol in over 23 000 patients: the GARDIAN study, a global multicentre, prospective, non-interventional study. Eur Radiol, 2017, 27(1): 286-295.
10. 马春忠, 高继斌. 含钆 MR 对比剂与肾源性系统性纤维化的关系. 中国临床医学影像杂志, 2009, 20(1): 53-54.
11. 许俊. 高浓度磁共振对比剂钆布醇的理化性质及临床应用. 放射学实践, 2016, 31(7): 666-669.
12. Hadizadeh DR, Jost G, Pietsch H, et al. Intraindividual quantitative and qualitative comparison of gadopentetate dimeglumine and gadobutrol in time-resolved contrast-enhanced 4-dimensional magnetic resonance angiography in minipigs. Invest Radiol, 2014, 49(7): 457-464.
13. Tombach B, Benner T, Reimer P, et al. Do highly concentrated gadolinium chelates improve MR brain perfusion imaging? Intraindividually controlled randomized crossover concentration comparison study of 0.5 versus 1.0 mol/L gadobutrol. Radiology, 2003, 226(3): 880-888.
14. Fabrega-Foster KE, Agarwal S, Rastegar N, et al. Efficacy and safety of gadobutrol-enhanced MRA of the renal arteries: Results from GRAMS (Gadobutrol-enhanced renal artery MRA study), a prospective, intraindividual multicenter phase 3 blinded study. J Magn Reson Imaging, 2018, 47(2): 572-581.
15. Luetkens JA, Kupczyk PA, Doerner J, et al. Respiratory motion artefacts in dynamic liver MRI: a comparison using gadoxetate disodium and gadobutrol. Eur Radiol, 2015, 25(11): 3207-3213.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Application value of gadobutrol in contrast-enhanced magnetic resonance angiography in abdominal artery angiography: a prospective multicenter study

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content